Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial
Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial
复制标题
DOI：
10.1159/000205582
复制
发表时间：
2009-01-01
影响因子：
2.8
通讯作者：
Tanaka, Toshio
中科院分区：
文献类型：
--
作者：
Kawai, Mari;Hirano, Toru;Tanaka, Toshio
背景：黄酮类化合物具有抗过敏和抗氧化作用。我们研究了酶修饰的异槲皮苷(EMIQ)，一种黄酮类化合物，缓解花粉症症状的效果。方法：在一项平行分组的双盲安慰剂对照研究设计中，20名患有日本雪松花粉症的受试者在花粉季节每天服用两粒100毫克EMIQ或一粒安慰剂，为期8周。每天记录主观症状和日常生活能力(ADL)评分，每4周进行一次生活质量评分。研究前后采血检测血清细胞因子、趋化因子、免疫球蛋白E、槲皮素和氧化生物标志物。结果：在整个研究期间，EMIQ组的总眼部评分和眼部瘙痒评分显著低于安慰剂组(p<；0.05)。在个别时段，EMIQ组的总症状评分显著低于安慰剂组(p<；0.05，4-5周)，而EMIQ组的其他评分，如鼻部总分(p=0.06，4-5周)、鼻塞评分(p=0.08，4-5周)、泪水评分(p=0.06，5-6周)、眼充血评分(p=0.08，4-7周)和ADL评分(p=0.08，4-7周)，均有降低的趋势。摄入EMIQ对血清细胞因子IL-4、IL-5、IL-12、IL-13、干扰素-γ、嗜酸性粒细胞趋化因子和IgE水平无明显下调作用，但可降低血清氧化低密度脂蛋白、胸腺和活化调节趋化因子水平。结论：服用槲皮素苷EMIQ是安全的，对花粉症引起的眼部症状有一定的影响。版权所有(C)2009 S.Karger AG，巴塞尔
Background: Flavonoids exert antiallergic and antioxidant effects. We investigated the efficacy of enzymatically modified isoquercitrin (EMIQ), a flavonoid, to relieve symptoms of pollinosis. Methods: In a parallel-group, double-blind placebo-controlled study design, 20 subjects with Japanese cedar pollinosis took two capsules daily of 100 mg EMIQ or a placebo for 8 weeks during the pollen season. Subjective symptoms and activities of daily living (ADL) scores were recorded every day, and the quality of life (QOL) score was obtained every 4 weeks. Blood sampling was performed before and after the study to measure serum cytokines, chemokines, IgE, quercetin and oxidized biomarkers. Results: During the entire study period, total ocular score and ocular itching score for the EMIQ group were significantly lower (p < 0.05) than for the placebo group. When limited to the individual periods, total symptom score for the EMIQ group was significantly lower (p < 0.05, week 4-5) than that for the placebo group while other scores for the EMIQ group, such as total nasal score (p = 0.06, week 4-5), nasal obstruction score (p = 0.08, week 4-5), lacrimation score (p = 0.06, week 5-6), ocular congestion score (p = 0.08, week 4-7) and ADL score (p = 0.08, week 4-7), all tended to be lower. The levels of serum cytokines such as interleukin (IL)-4, IL-5, IL-12, IL-13, interferon-gamma, and eotaxin and IgE were not significantly downregulated by the intake of EMIQ but the serum concentrations of oxidized low-density lipoprotein and thymus and activation-regulated chemokine were reduced. Conclusion: Intake of the quercetin glycoside EMIQ was safe and influenced ocular symptoms caused by pollinosis. Copyright (C) 2009 S. Karger AG, Basel